Polymyalgia Rheumatica Diagnosis and Evaluation

Rheumatology treats musculoskeletal and autoimmune diseases, including arthritis, lupus, gout, and vasculitis.

Diagnosis and Evaluation for Polymyalgia Rheumatica

Accurate diagnosis and evaluation of polymyalgia rheumatica (PMR) is essential for initiating timely therapy and preventing complications. This page is designed for international patients and their caregivers who seek a clear understanding of how clinicians identify and monitor this inflammatory condition. Approximately 10 % of individuals over 65 develop PMR, and early recognition can reduce pain, stiffness, and the need for prolonged high‑dose steroids. Below, we outline the step‑by‑step approach used by the rheumatology team at Liv Hospital, from the first clinical impression to long‑term follow‑up.

Our comprehensive overview combines clinical expertise with evidence‑based protocols, ensuring that patients receive a personalized assessment aligned with international standards. Whether you are preparing for a consultation or reviewing your treatment plan, the information presented here will help you navigate the diagnostic pathway with confidence.

Clinical Presentation and Initial Assessment

The first pillar of diagnosis and evaluation lies in a thorough history and physical examination. Polymyalgia rheumatica typically presents with abrupt onset of bilateral shoulder and pelvic girdle pain, accompanied by morning stiffness lasting more than 45 minutes. Key clinical features include:

• Diffuse aching in the neck, shoulders, upper arms, and hips.
• Rapid improvement after initiating low‑dose corticosteroids.
• Absence of joint swelling or erosive changes on examination.
• Systemic symptoms such as low‑grade fever, fatigue, and weight loss.

During the physical exam, physicians assess range of motion, palpate tender areas, and check for associated conditions like giant cell arteritis. The assessment also records comorbidities that may influence treatment choices, such as diabetes or osteoporosis.

Documenting the timeline of symptom development is crucial. Patients often report that symptoms began within the past two weeks, a pattern that helps differentiate PMR from other rheumatic diseases that evolve more slowly.

Typical Symptoms

Symptoms are usually symmetrical and may include:

• Shoulder girdle pain that radiates to the upper arms.
• Hip and thigh discomfort limiting walking.
• Neck stiffness that interferes with daily activities.

Physical Examination Findings

Physical findings often reveal:

• Limited active shoulder abduction (>30° reduction compared with the opposite side).
• Tenderness over the deltoid and trochanteric regions without swelling.
• Normal joint effusions, helping to exclude rheumatoid arthritis.

Laboratory Tests and Biomarkers

Laboratory investigations provide objective evidence of inflammation and help rule out mimicking disorders. The most informative markers in the diagnosis and evaluation of PMR are:

• Erythrocyte Sedimentation Rate (ESR) – usually markedly elevated (often >40 mm/h).
• C‑reactive Protein (CRP) – parallel rise with ESR, reflecting acute‑phase response.
• Complete Blood Count (CBC) – may show mild anemia of chronic disease.
• Liver function tests – occasional mild transaminitis.

While these tests are not disease‑specific, their combined pattern supports the clinical suspicion of PMR. In rare cases, additional serologic studies (e.g., rheumatoid factor, anti‑CCP) are ordered to exclude rheumatoid arthritis.

Repeated testing after initiating therapy helps confirm the diagnosis; a rapid decline in ESR and CRP within 2–4 weeks is characteristic of PMR.

Imaging Studies in Diagnosis

Imaging is not mandatory for the primary diagnosis and evaluation of polymyalgia rheumatica, but it plays a valuable role when the clinical picture is ambiguous or when clinicians need to exclude alternative pathologies.

• Ultrasound – Detects subdeltoid bursitis, trochanteric bursitis, and tenosynovitis, which are common in PMR.
• MRI – Highlights inflammation of the peri‑articular soft tissues and can differentiate PMR from early rheumatoid arthritis.
• FDG‑PET/CT – Shows increased uptake in large joints and the aorta, useful when giant cell arteritis is suspected.

Below is a comparison of imaging modalities frequently employed in the work‑up of PMR:

When imaging confirms peri‑articular inflammation without erosive changes, it reinforces the clinical diagnosis and guides the rheumatology team at Liv Hospital in tailoring treatment.

Differential Diagnosis: Excluding Mimicking Conditions

Polymyalgia rheumatica shares several features with other rheumatic and musculoskeletal disorders. A systematic differential diagnosis ensures that patients receive the most appropriate therapy.

• Rheumatoid arthritis – Typically presents with joint swelling and seropositivity (RF, anti‑CCP).
• Late‑onset systemic lupus erythematosus – May cause myalgia but often includes malar rash and renal involvement.
• Fibromyalgia – Diffuse pain without inflammatory markers; symptoms are chronic rather than acute.
• Shoulder osteoarthritis – Localized joint degeneration with radiographic changes.
• Giant cell arteritis (GCA) – Overlaps with PMR but presents with temporal headache, visual loss, and elevated ESR.

The table below highlights key distinguishing features:

By systematically ruling out these alternatives, the rheumatology specialists at Liv Hospital can confidently confirm PMR and avoid unnecessary immunosuppression.

Follow‑Up Evaluation and Monitoring Response to Treatment

After establishing the diagnosis, ongoing evaluation focuses on treatment response, steroid tapering, and detection of complications. The standard follow‑up schedule includes:

• First review 2 weeks after starting prednisone (10–20 mg/day).
• Subsequent visits at 4‑week intervals until ESR/CRP normalize.
• Quarterly assessments during tapering phase.
• Annual bone density scan to monitor osteoporosis risk.

During each visit, clinicians reassess pain scores, morning stiffness duration, and functional ability using validated tools such as the Health Assessment Questionnaire (HAQ). Laboratory monitoring repeats ESR and CRP to ensure inflammatory markers remain within normal limits.

Potential adverse effects of long‑term corticosteroids are proactively managed. Liv Hospital offers integrated services—including endocrinology consultation, physiotherapy, and nutrition counseling—to mitigate risks such as hyperglycemia, hypertension, and bone loss.

Patients who experience a relapse (return of symptoms or rise in inflammatory markers) may require a temporary increase in steroid dosage or the addition of steroid‑sparing agents like methotrexate. The personalized care pathway ensures that each individual receives the minimal effective dose while maintaining quality of life.

Why Choose Liv Hospital?

Liv Hospital combines JCI accreditation, a multilingual care team, and state‑of‑the‑art facilities to deliver world‑class rheumatology services to international patients. Our specialists follow evidence‑based protocols, provide coordinated logistics—from airport transfer to interpreter support—and tailor each treatment plan to the unique needs of patients traveling from abroad.

Ready to schedule your comprehensive evaluation for polymyalgia rheumatica? Contact Liv Hospital today to arrange a personalized appointment and experience seamless, expert care from the moment you arrive.